Skip to main content

Advertisement

SpringerLink
Log in

Primary aldosteronism and salt

  • Invited Review
  • Published:
Pflügers Archiv - European Journal of Physiology Aims and scope Submit manuscript

Abstract

For many years, primary aldosteronism was thought (and taught) to be a relatively rare (<1 %) and benign form of high blood pressure: now we know that neither is the case. Currently, the prevalence is considered to be 5–10 % of hypertensives, on the basis of more or less stringent cutoffs for the aldosterone/renin ratio and plasma aldosterone concentration: increasingly, evidence is mounting that the true prevalence of (relatively) autonomous aldosterone secretion may be ∼30 % of hypertensives. There is, in addition, a consensus that the risk profile for patients with primary aldosteronism is substantially higher than in age-, sex-, and blood pressure-matched essential hypertensives; the cardiovascular/renal damage in primary aldosteronism is thus not a primary effect of raised blood pressure. The nexus between salt and primary aldosteronism is clear, as equivalently raised or even higher levels of plasma aldosterone in chronic sodium deficiency are homeostatic and do not cause cardiovascular damage, thus ruling out deleterious effects of aldosterone acting alone. In primary aldosteronism the normal homeostatic feedback loops between sodium status and aldosterone levels are disturbed, so that cardiovascular/renal damage reflects inappropriate aldosterone levels for sodium status. One possible actor in such a scenario is endogenous ouabain (or similar compounds), which is elevated in the sodium-loaded state and a vasoconstrictor, and thus potentially be able both to raise blood pressure and to cause cardiovascular/renal damage. A second consideration is that of the epidemiologic data linking a chronically high salt intake to a raised blood pressure. If autonomous aldosterone secretion is in fact present in ∼30 % of hypertensives, this may be the group sensitive to the pressor effects of high salt, with the remainder much less affected. Finally, at a practical level given even the currently accepted prevalence of primary aldosteronism, a radical reconsideration of first-line antihypertensive therapy is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser M (2014) Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 99(8):2745–2753. doi:10.1210/jc.2014-1153

    Article  CAS  PubMed  Google Scholar 

  2. Amar L, Azizi M, Menard J, Peyrard S, Plouin PF (2013) Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens 31(3):624–629. doi:10.1097/HJH.0b013e32835d6d49, discussion 629

    Article  CAS  PubMed  Google Scholar 

  3. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237(4812):268–275

    Article  CAS  PubMed  Google Scholar 

  4. Asayama K, Stolarz-Skrzypek K, Persu A, Staessen JA (2014) Systematic review of health outcomes in relation to salt intake highlights the widening divide between guidelines and the evidence. Am J Hypertens 27(9):1138–1142. doi:10.1093/ajh/hpu126

    Article  PubMed  Google Scholar 

  5. Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120(6):893–901

    CAS  PubMed  Google Scholar 

  6. Conn JW (1955) Primary Aldosteronism, a new clinical syndrome. J Lab Med 45(1):3–17

    CAS  Google Scholar 

  7. Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB (2005) The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci U S A 102(44):15845–15850

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C (1988) Localisation of 11 beta-hydroxysteroid dehydrogenase—tissue specific protector of the mineralocorticoid receptor. Lancet 2(8618):986–989

    Article  CAS  PubMed  Google Scholar 

  9. Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, Jerums G (2011) Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 34(3):703–709. doi:10.2337/dc10-1723

    Article  PubMed Central  PubMed  Google Scholar 

  10. Funder JW (2012) Primary aldosteronism: are we missing the wood for the trees? Horm Metab Res 44(3):251–253. doi:10.1055/s-0031-1301281

    Article  CAS  PubMed  Google Scholar 

  11. Funder JW (2013) Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 6:129–138. doi:10.2147/IBPC.S13783, Review

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Funder JW (2014) Sensitivity to aldosterone: plasma levels are not the full story. Hypertension 63(6):1168–1170. doi:10.1161/HYPERTENSIONAHA.114.03127

    Article  CAS  PubMed  Google Scholar 

  13. Funder JW, Carey RM, Fardella C et al (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:3266–3281. doi:10.1210/jc.2008-0104

    Article  CAS  PubMed  Google Scholar 

  14. Funder JW, Feldman D, Edelman IS (1973) The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 92(4):994–1004

    Article  CAS  PubMed  Google Scholar 

  15. Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242(4878):583–585

    Article  CAS  PubMed  Google Scholar 

  16. Gómez-Sánchez EP, Venkataraman MT, Thwaites D, Fort C (1990) ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 258(4 Pt 1):E649–E653

    PubMed  Google Scholar 

  17. Gouli A, Kaltsas G, Tzonou A et al (2011) High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Investig 41(11):1127–1136. doi:10.1111/j.1365-2362.2011.02531.x

    Article  Google Scholar 

  18. Hannemann A, Wallaschofski H (2012) Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies—a review of the current literature. Horm Metab Res 44:157–162. doi:10.1055/s-0031-1295438

    Article  CAS  PubMed  Google Scholar 

  19. Hasegawa T, Masugi F, Ogihara T, Kumahara Y (1987) Increase in plasma ouabainlike inhibitor of Na+, K+−ATPase with high sodium intake in patients with essential hypertension. J Clin Hypertens 3(4):419–429

    CAS  PubMed  Google Scholar 

  20. He FJ, Li J, Macgregor GA (2013) Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 4:CD004937. doi:10.1002/14651858.CD004937.pub2, Review

    PubMed  Google Scholar 

  21. Helber A, Wambach G, Hummerich W, Bšnner G, Meurer KA, Kaufmann W (1980) Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 58(9):439–447, No abstract available

    Article  CAS  PubMed  Google Scholar 

  22. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyana T (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med 141:1589–1593

    Article  CAS  PubMed  Google Scholar 

  23. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y (2011) Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 34(1):98–102. doi:10.1038/hr.2010.166

    Article  CAS  PubMed  Google Scholar 

  24. Kagawa CMBD (1964) Relationship of plasma aldadiene levels and antimineralocorticoid effects of spironolactone in the laboratory. Proc Soc Exp Biol Med 115:837–840

    Article  CAS  PubMed  Google Scholar 

  25. Kaplan NM (2012) Primary aldosteronism: evidence against a second epidemic. J Hypertens 30(10):1899–1902. doi:10.1097/HJH.0b013e3283559a03

    Article  CAS  PubMed  Google Scholar 

  26. Kassahn KS, Ragan MA, Funder JW (2011) Mineralocorticoid receptors: evolutionary and pathophysiological considerations. Endocrinology 152(5):1883–1890. doi:10.1210/en.2010-1444

    Article  CAS  PubMed  Google Scholar 

  27. Kempers MJ, Lenders JW, van Outhousden L, van der Wilt GJ, Schultze Kool LJ, Hermus KR, Deinum J (2009) Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 151(5):329–337, Review

    Article  PubMed  Google Scholar 

  28. Krozowski ZS, Funder JW (1983) Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci U S A 80(19):6056–6060

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Kÿpers EM, Amar L, Raynaud A, Plouin PF, Steichen O (2012) A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab 97(10):3530–3537. doi:10.1210/jc.2012-1917

    Article  Google Scholar 

  30. Laredo J, Shah JR, Lu ZR, Hamilton BP, Hamlyn JM (1997) Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension 29(1 Pt 2):401–407

    Article  CAS  PubMed  Google Scholar 

  31. Le Loan TY, Mardini M, Howell VM, Funder JW, Ashton AW, Mihailidou AS (2012) Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension 59(6):1164–1169. doi:10.1161/HYPERTENSIONAHA.111.190488

    Article  Google Scholar 

  32. Levy D, Rocha R, Funder JW (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89:2736–2740

    Article  CAS  PubMed  Google Scholar 

  33. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, SchŸtz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83(6):835–839

    Article  CAS  PubMed  Google Scholar 

  34. Mihailidou AS, Le TYL, Mardini M, Funder JW (2009) Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6):1306–1312. doi:10.1161/HYPERTENSIONAHA.109.136242

    Article  CAS  PubMed  Google Scholar 

  35. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243–1248

    Article  CAS  PubMed  Google Scholar 

  36. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A (2011) Task force committee on primary Aldosteronism, the Japan endocrine society. Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. Endocr J 58(9):711–721

    Article  CAS  PubMed  Google Scholar 

  37. Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16(11 Pt 1):925–930

    Article  CAS  PubMed  Google Scholar 

  38. Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H (2013) Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 28(7):1787–1793. doi:10.1093/ndt/gfs587

    Article  CAS  PubMed  Google Scholar 

  39. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453–2463. doi:10.1093/eurheartj/eht187

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Pollan M (2013) Cooked: a natural history of transformation. Penguin, New York

  41. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93(1):69–76

    Article  CAS  PubMed  Google Scholar 

  42. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54(3):537–543. doi:10.1161/HYPERTENSIONAHA.109.131110

    Article  CAS  PubMed  Google Scholar 

  43. Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, Reincke M, Quinkler M (2014) Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 99(6):E1035–E1039. doi:10.1210/jc.2013-3789

    Article  CAS  PubMed  Google Scholar 

  44. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al (2006) A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 48:2293–2300

    Article  CAS  PubMed  Google Scholar 

  45. Savard S, Amar L, Plouin PF, Steichen O (2013) Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62(2):331–336. doi:10.1161/HYPERTENSIONAHA.113.01060

    Article  CAS  PubMed  Google Scholar 

  46. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T (1953) Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf din Mineralsoffwechsel. Experientia 9(9):333–335

    Article  CAS  PubMed  Google Scholar 

  47. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH (2005) Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90(9):5070–5076

    Article  CAS  PubMed  Google Scholar 

  48. Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, Dimeglio LA, Jung J, Pratt JH (2014) Racial differences in sensitivity of blood pressure to aldosterone. Hypertension 63(6):1212–1218. doi:10.1161/HYPERTENSIONAHA.113.02989

    Article  CAS  PubMed  Google Scholar 

  49. Young M, Funder JW (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145(7):3153–3157

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MIMR-PHI Institute (formerly Prince Henry’s Institute), 27-31 Wright Street, Clayton, VIC, 3168, Australia

    John W. Funder

Authors
  1. John W. Funder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. Funder.

Additional information

This article is published as part of the Special Issue on Salt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Funder, J.W. Primary aldosteronism and salt. Pflugers Arch - Eur J Physiol 467, 587–594 (2015). https://doi.org/10.1007/s00424-014-1658-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00424-014-1658-0

Keywords

Search

Navigation